Medizinische Universität Graz - Research portal
Navigation/Search
- Researchers
- Institutions
- Projects
- Publications
- Partners
- Sponsors
- Equipment
- Knowhow
- Fields of Research
"Faces" of the day:
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Bereczki, D; Dénes, Á; Boneschi, FM; Akhvlediani, T; Cavallieri, F; Fanciulli, A; Filipović, SR; Guekht, A; Helbok, R; Hochmeister, S; von, Oertzen, TJ; Özturk, S; Priori, A; Rakusa, M; Willekens, B; Moro, E; Sellner, J, , NeuroCOVID-19, Task, Force, of, the, European, Academy, of, Neurology.
Need for awareness and surveillance of long-term post-COVID neurodegenerative disorders. A position paper from the neuroCOVID-19 task force of the European Academy of Neurology.
J Neurol. 2025; 272(6): 380
Doi: 10.1007/s00415-025-13110-3
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Hochmeister Sonja
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Neuropathological and clinical studies suggest that infection with SARS-CoV-2 may increase the long-term risk of neurodegeneration. METHODS: We provide a narrative overview of pathological and clinical observations justifying the implementation of a surveillance program to monitor changes in the incidence of neurodegenerative disorders in the years after COVID-19. RESULTS: Autopsy studies revealed diverse changes in the brain, including loss of vascular integrity, microthromboses, gliosis, demyelination, and neuronal- and glial injury and cell death, in both unvaccinated and vaccinated individuals irrespective of the severity of COVID-19. Recent data suggest that microglia play an important role in sustained COVID-19-related inflammation, which contributes to the etiology initiating a neurodegenerative cascade, to the worsening of pre-existing neurodegenerative disease or to the acceleration of neurodegenerative processes. Histopathological data have been supported by neuroimaging, and epidemiological studies also suggested a higher risk for neurodegenerative diseases after COVID-19. CONCLUSIONS: Due to the high prevalence of COVID-19 during the pandemic, healthcare systems should be aware of, and be prepared for a potential increase in the incidence of neurodegenerative diseases in the upcoming years. Strategies may include follow-up of well-described cohorts, analyses of outcomes in COVID-19-registries, nationwide surveillance programs using record-linkage of ICD-10 diagnoses, and comparing the incidence of neurodegenerative disorders in the post-pandemic periods to values of the pre-pandemic years. Awareness and active surveillance are particularly needed, because diverse clinical manifestations due to earlier SARS-CoV-2 infections may no longer be quoted as post-COVID-19 symptoms, and hence, increasing incidence of neurodegenerative pathologies at the community level may remain unnoticed.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- COVID-19 - complications, epidemiology
- Neurodegenerative Diseases - epidemiology, etiology, pathology
- Europe - epidemiology
- Neurology - standards
- Advisory Committees - administration & dosage
- Find related publications in this database (Keywords)
- Awareness
- Surveillance
- Inflammation
- Neurodegeneration
- SARS-CoV-2